ROI
Roivant Sciences
Stock
Stock
ISIN: BMG762791017
Ticker: ROIV
BMG762791017
ROIV
Price
Price
CHART BY
Frequently asked questions
What is Roivant Sciences's market capitalization?
The market capitalization of Roivant Sciences is $7.70B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Roivant Sciences?
Roivant Sciences's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.145. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Roivant Sciences's stock?
Currently, 10 analysts cover Roivant Sciences's stock, with a consensus target price of $16.75. Analyst ratings provide insights into the stock's expected performance.
What is Roivant Sciences's revenue over the trailing twelve months?
Over the trailing twelve months, Roivant Sciences reported a revenue of $97.56M.
What is the EBITDA for Roivant Sciences?
Roivant Sciences's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$1.10B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Roivant Sciences?
Roivant Sciences has a free cash flow of -$779.48M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Roivant Sciences have, and what sector and industry does it belong to?
Roivant Sciences employs approximately 908 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Roivant Sciences's shares?
The free float of Roivant Sciences is 438.37M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $7.70B
- EPS (TTM)
- -$0.145
- Free Float
- 438.37M
- Revenue (TTM)
- $97.56M
- EBITDA (TTM)
- -$1.10B
- Free Cashflow (TTM)
- -$779.48M
Pricing
- 1D span
- $10.59$10.89
- 52W span
- $8.73$13.05
Analyst Ratings
The price target is $16.75 and the stock is covered by 10 analysts.
Buy
9
Hold
1
Sell
0
Information
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
- Employees
- 908
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- BMG762791017
- Primary Ticker
- ROIV
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet